Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.

about

Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.

Item

http://www.wikidata.org/entity/Q40330547

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Impact of treatment variabilit ...... mary central nervous lymphoma.

@en

type

Item

label

Impact of treatment variabilit ...... mary central nervous lymphoma.

@en

prefLabel

Impact of treatment variabilit ...... mary central nervous lymphoma.

@en

P1476

Impact of treatment variabilit ...... mary central nervous lymphoma.

@en

P2093

Adam M Petrich

http://www.w3.org/2001/XMLSchema#string

Chadi Nabhan

http://www.w3.org/2001/XMLSchema#string

David Peace

http://www.w3.org/2001/XMLSchema#string

Jeffrey Raizer

http://www.w3.org/2001/XMLSchema#string

Leo I Gordon

http://www.w3.org/2001/XMLSchema#string

Parameswaran Venugopal

http://www.w3.org/2001/XMLSchema#string

Rimas Lukas

http://www.w3.org/2001/XMLSchema#string

Sanjib Basu

http://www.w3.org/2001/XMLSchema#string

Vineela Chukkapalli

http://www.w3.org/2001/XMLSchema#string

P2860

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.

Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment

High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.

P304

72-79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14522

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P50

Reem Karmali

P577

2017-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28211579

http://www.w3.org/2001/XMLSchema#string